Christopher W. Murray

Cedars-Sinai Smidt Heart Institute — United States

Computer Science · Physical Sciences

62h-index19.8kcitations157works10.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(64), Protein Structure and Dynamics(24), Advanced Chemical Physics Studies(18), Chemical Synthesis and Analysis(18), Click Chemistry and Applications(18)

Publications157 total

High-Throughput Workflow for Detergent-free Cell-Based Proteomic Characterization
Journal of Proteome Research·2025
Return to Flatland
Nature Reviews Chemistry·2025· 24 cited
Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase
Journal of Medicinal Chemistry·2024· 8 citedOpen Access
Data from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplementary Methods from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplementary Tables 1-6 from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplemental Figure 1 from Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
2023Open Access
Data from Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
2023Open Access
Supplementary Tables 1-6 from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Data from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplemental Table 4 from Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
2023Open Access
X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent Inhibitor
Journal of Medicinal Chemistry·2022· 23 citedOpen Access
Meaningful machine learning models and machine-learned pharmacophores from fragment screening campaigns
arXiv (Cornell University)·2022· 6 citedOpen Access
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Journal of Medicinal Chemistry·2021· 17 citedOpen Access
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Molecular Cancer Therapeutics·2021· 32 citedOpen Access
Fragment-based drug discovery: opportunities for organic synthesis
RSC Medicinal Chemistry·2020· 71 citedOpen Access
Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design
Drug Discovery Today·2019· 95 citedOpen Access
A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA
MedChemComm·2019· 76 cited
ERK2 mini-fragment binding
2018· 46 cited
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Journal of Medicinal Chemistry·2018· 63 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Miles Congreve(11), Marcel L. Verdonk(9), Gianni Chessari(9), Nicholas C. Handy(8), Michael J. Hartshorn(7), Martyn Frederickson(7), Robin A. E. Carr(6), Harren Jhoti(6), David C. Rees(6), Sahil Patel(6), Roger D. Amos(6), Paul N. Mortenson(5), Gregory J. Laming(5), Jason C. Cole(4), Richard D. Taylor(4), Anne Cleasby(4), Andrew Woodhead(4), Maria G. Carr(4), Rachel McMenamin(4), Owen Callaghan(4)